Uppsala Reports editor
@UMCGlobalSafety
Medicine safety monitoring is important in every stage of drug development, from pre-marketing clinical trials to post-marketing analyses. Yet, certain factors in their design can greatly impact its effectiveness, such as the diversity of the study population, or the complexity of its methodology.
All this and more is discussed in the latest Drug Safety Matters podcast episode, where Marianne Lunzer from AGES and Sanja Prpić from HALMED, review the pros and cons of various study types and the importance of testing medicines on diverse populations, as well as how pre and post-marketing studies are linked to give a more comprehensive picture of patient safety.
Subscribe by visiting the Drug Safety Matters website or listen to the podcast here: